Prior art

To identify the most relevant prior art for US patent 12295968, I would typically access the patent document itself on the USPTO database (such as Patent Public Search) to review the "References Cited" section. This section, provided by the patent examiner and potentially the applicant, lists the prior art considered during prosecution.

Since I do not have direct access to the live USPTO database or the specific "References Cited" section for patent 12295968, I cannot provide a detailed breakdown of each prior art citation with publication/filing dates, descriptions, and specific claims potentially anticipated under 35 U.S.C. § 102.

However, based on the information provided in the patent text itself, the "Prior art keywords" listed are: "tumor", "seq", "cells", "antibody", and "tgf". These keywords suggest that relevant prior art would likely involve compositions and methods related to:

• Tumor biology and cancer treatment.
• Sequences (likely amino acid or nucleic acid sequences) relevant to the described molecules.
• Cellular mechanisms and interactions, especially in the context of the immune system and cancer.
• Antibodies, given that the patent describes targeted immunomodulatory antibodies and fusion proteins.
• Transforming growth factor-beta (TGF-β), as it is explicitly mentioned as an immunomodulatory moiety and a key immunosuppressive cytokine.

To accurately determine which claims are potentially anticipated, a thorough analysis of each cited prior art document in relation to the specific language of each claim of US12295968 would be required. This process typically involves:

1. Retrieving the full text of each cited prior art patent or publication.
2. Comparing the disclosures in the prior art to the elements of each claim in US12295968.
3. Determining if every element of a claim is found, either explicitly or inherently, in a single piece of prior art (anticipation under 35 U.S.C. § 102).